Madrigal Pharmaceuticals (NASDAQ:MDGL) Price Target Raised to $633.00

Madrigal Pharmaceuticals (NASDAQ:MDGL) had its target price increased by equities researchers at Canaccord Genuity Group from $612.00 to $633.00 in a research report issued on Wednesday, Benzinga reports. The brokerage presently has a “buy” rating on the biopharmaceutical company’s stock. Canaccord Genuity Group‘s price target would indicate a potential upside of 58.08% from the stock’s current price.

A number of other equities analysts also recently issued reports on MDGL. Truist Financial reaffirmed a “buy” rating and issued a $743.00 price target (up from $709.00) on shares of Madrigal Pharmaceuticals in a report on Wednesday. Weiss Ratings restated a “sell (d-)” rating on shares of Madrigal Pharmaceuticals in a research report on Thursday, October 15th. Barclays lowered their target price on shares of Madrigal Pharmaceuticals from $964.00 to $962.00 and set an “overweight” rating for the company in a report on Monday, August 3rd. UBS Group reaffirmed a “buy” rating and issued a $735.00 target price on shares of Madrigal Pharmaceuticals in a research report on Wednesday, October 14th. Finally, HC Wainwright reiterated a “buy” rating on shares of Madrigal Pharmaceuticals in a research note on Friday, July 31st. Fourteen investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the company presently has a consensus rating of “Moderate Buy” and an average target price of $706.87.

Madrigal Pharmaceuticals Stock Up 1.0%

NASDAQ MDGL traded up $4.11 during trading on Wednesday, reaching $400.43. 2,313,643 shares of the company’s stock were exchanged, compared to its average volume of 347,010. The company has a 50 day moving average price of $494.64 and a two-hundred day moving average price of $498.92. The stock has a market cap of $9.25 billion, a P/E ratio of -31.07 and a beta of -0.98. Madrigal Pharmaceuticals has a 1 year low of $353.54 and a 1 year high of $615.00. The company has a debt-to-equity ratio of 0.65, a quick ratio of 2.94 and a current ratio of 3.20.

Madrigal Pharmaceuticals (NASDAQ:MDGL) last released its quarterly earnings data on Tuesday, November 3rd. The biopharmaceutical company reported $1.83 EPS for the quarter, beating analysts’ consensus estimates of ($1.09) by $2.92. Madrigal Pharmaceuticals had a negative return on equity of 56.65% and a negative net margin of 25.32%. The business had revenue of $431.27 million for the quarter, compared to the consensus estimate of $404.17 million. During the same quarter in the prior year, the business posted ($5.08) EPS. On average, equities research analysts anticipate that Madrigal Pharmaceuticals will post -7.03 EPS for the current fiscal year.

Insider Buying and Selling

In other Madrigal Pharmaceuticals news, CEO William Sibold sold 6,362 shares of the business’s stock in a transaction that occurred on Wednesday, September 9th. The stock was sold at an average price of $535.59, for a total value of $3,407,423.58. Following the completion of the sale, the chief executive officer owned 202,967 shares in the company, valued at approximately $108,707,095.53. The trade was a 3.04% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, General Counsel Shannon T. Kelley sold 664 shares of the business’s stock in a transaction that occurred on Monday, August 17th. The shares were sold at an average price of $514.97, for a total value of $341,940.08. Following the completion of the sale, the general counsel owned 11,474 shares of the company’s stock, valued at approximately $5,908,765.78. This represents a 5.47% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold a total of 12,247 shares of company stock worth $6,581,182 in the last 90 days. 17.60% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On Madrigal Pharmaceuticals

A number of institutional investors have recently modified their holdings of the business. J. Goldman & Co LP acquired a new stake in Madrigal Pharmaceuticals during the 2nd quarter worth $2,722,000. Royal Bank of Canada grew its position in Madrigal Pharmaceuticals by 22.5% during the 1st quarter. Royal Bank of Canada now owns 12,526 shares of the biopharmaceutical company’s stock worth $6,557,000 after purchasing an additional 2,303 shares during the last quarter. Hsbc Holdings PLC increased its stake in Madrigal Pharmaceuticals by 1,738.3% in the second quarter. Hsbc Holdings PLC now owns 20,240 shares of the biopharmaceutical company’s stock valued at $10,868,000 after purchasing an additional 19,139 shares during the period. Sivik Global Healthcare LLC acquired a new position in Madrigal Pharmaceuticals in the third quarter valued at $1,260,000. Finally, Legal & General Group Plc acquired a new position in Madrigal Pharmaceuticals in the second quarter valued at $6,630,000. 98.50% of the stock is owned by institutional investors and hedge funds.

More Madrigal Pharmaceuticals News

Here are the key news stories impacting Madrigal Pharmaceuticals this week:

• Positive Sentiment: Q3 results beat expectations. Madrigal reported earnings of $1.83 per share, versus analysts’ expected loss of $1.09, and revenue of $431.27 million, above the $404.17 million consensus. Rezdiffra sales rose 50%, surpassing $1 billion, supporting the case that the drug’s commercial ramp is driving a turnaround. Madrigal Q3 results
• Positive Sentiment: Analysts raised targets and maintained bullish ratings. Truist reaffirmed Buy and lifted its target to $743; Citi previously raised its target to $760, also with a Buy rating. Such views may support sentiment, though targets are not guarantees. Truist rating
• Neutral Sentiment: Pipeline plans offer longer-term potential, but key data are not imminent. Madrigal expects MAESTRO-NASH OUTCOMES results in late 2027 and is planning a large MAESTRO-CSPH study. These programs could broaden future opportunity, while the readout timeline leaves room for uncertainty. Pipeline update
• Negative Sentiment: Profitability concerns and legal scrutiny remain risks. Coverage noted investor concerns about near-term profitability despite the reported quarterly earnings beat. Separately, Kaplan Fox announced an investigation into potential securities-law violations; the announcement does not establish that wrongdoing occurred. Investigation announcement

About Madrigal Pharmaceuticals

Madrigal Pharmaceuticals, Inc is a biopharmaceutical company focused on developing and commercializing medicines for nonalcoholic steatohepatitis, now known as metabolic dysfunction-associated steatohepatitis (MASH), and other chronic liver diseases. The company is headquartered in West Conshohocken, Pennsylvania.

Madrigal’s lead product is Rezdiffra (resmetirom), an orally administered thyroid hormone receptor beta agonist designed to target key drivers of liver disease, including hepatic fat accumulation and fibrosis.